| BERENBERG stuft STMicro auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für STMicroelectronics auf "Buy" mit einem Kursziel von 53 Euro belassen. Hersteller von analogen Chips wie Infineon oder STMicroelectronics... ► Artikel lesen |
| UBS stuft STMicro auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat STMicroelectronics auf "Buy" mit einem Kursziel von 49 Euro belassen. Der Chiphersteller habe zu einer Telefonkonferenz über seine Produktreihe... ► Artikel lesen |
| Aktien Europa: Moderate Verluste - Auto- und Versorgeraktien schwächeln | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die Aktienmärkte in Europa haben am Montag überwiegend nachgegeben. Sie litten unter der nach wie vor unklaren Lage im Nahen Osten und damit einhergehenden erneut steigenden... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen |
| Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen |
| Akeso, Inc.: Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) | Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM)... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) | Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive... ► Artikel lesen |